Methods:

This is an analysis from the PARTNER 3 trial, a multicenter, prospective, randomized trial examining SAVR versus TAVR with a balloon-expandable valve in patients with severe aortic stenosis at low surgical risk for mortality from SAVR. Patients who experienced POAF at any time following the index procedure and up to 1 year later were grouped into: 1) early, 2) late, and 3) any POAF. Those with pre-existing AF and those who did not undergo AVR were excluded. The primary endpoint was a composite of all-cause mortality, stroke, or rehospitalization at 2 years. Secondary endpoints were rehospitalization for procedure- or device-related adverse events or heart failure, all-cause death, cardiovascular death, stroke, and major bleeding.

Analysis was performed in the as-treated population. Logistic regression was used to predict early, late, and any POAF with a model adjusting for age, sex, history of diabetes, history of hypertension, history of congestive heart failure, history of stroke or transient ischemic attack, body mass index, baseline hemoglobin, creatinine clearance, left ventricular ejection fraction, left atrial volume (LAV), and treatment modality. Multivariable Cox proportional hazards regression analysis was used to examine the association between POAF and adverse clinical outcomes.